Therefore, the inability to clear fibronectin aggregates in chronic MS lesions is likely attributed to the lack of an appropriate protease, for example, MMP7, rather than to the inability to clear dimeric fibronectin. This evidence concerns the gene MMP7 and myeloid sarcoma.